Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114,331,829
-
Total 13F shares
-
100,983,215
-
Share change
-
+4,329,391
-
Total reported value
-
$3,912,460,118
-
Put/Call ratio
-
58%
-
Price per share
-
$38.77
-
Number of holders
-
230
-
Value change
-
+$152,790,990
-
Number of buys
-
122
-
Number of sells
-
101
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q1 2022
As of 31 Mar 2022,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
230 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
100,983,215 shares.
The largest 10 holders included
Redmile Group, LLC, ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, Capital World Investors, Bellevue Group AG, STATE STREET CORP, Casdin Capital, LLC, and JOHNSON & JOHNSON.
This page lists
232
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.